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A B S T R A C T
Glioblastoma is a devastating primary brain tumor resistant to conventional therapies. In this study, we
tested the eﬃcacy of combining temozolomide with curcumin, a phytochemical known to inhibit glio-
blastoma growth, and investigated the mechanisms involved. The data showed that synergy between
curcumin and temozolomide was not achieved due to redundant mechanisms that lead to activating pro-
tective autophagy both in vitro and in vivo. Autophagy preceded apoptosis, and blocking this response
with autophagy inhibitors (3-methyl-adenine, ATG7 siRNA and chloroquine) rendered cells susceptible
to temozolomide and curcumin alone or combinations by increasing apoptosis. While curcumin inhib-
ited STAT3, NFκB and PI3K/Akt to affect survival, temozolomide-induced autophagy relied on the DNA
damage response and repair components ATM and MSH6, as well as p38 and JNK1/2. However, the most
interesting observation was that both temozolomide and curcumin required ERK1/2 to induce au-
tophagy. Blocking this ERK1/2-mediated temozolomide and curcumin induced autophagy with resveratrol,
a blood–brain barrier permeable drug, improved temozolomide/curcumin eﬃcacy in brain-implanted
tumors. Overall, the data presented demonstrate that autophagy impairs the eﬃcacy of temozolomide/
curcumin, and inhibiting this phenomenon could provide novel opportunities to improve brain tumor
treatment.
© 2014 Elsevier Ireland Ltd. All rights reserved.
Introduction
Over the last decade, cumulating evidences have shown that
curcumin is active against a variety of cancers in vitro and in vivo
[1]. The ability to interfere with pathways that are overexpressed
in cancer cells, such as NFκB, STAT3, Sonic Hedgehog and PI3K/
Akt, contributes to the selectivity of curcumin in inducing cell
death in tumors while sparing healthy tissues [2]. Our group has
sought to understand the mechanisms whereby curcumin affects
glioblastoma cells, aiming to use this knowledge for therapeutic
advantage. We have reported that, despite the concerns regarding
its oral bioavailability [1], intraperitoneally administrated curcumin
is able to decrease brain-implanted glioblastomas in rats [3]. Cor-
roborating these results, other groups have shown similar dose–
effect patterns of anticancer activity in other preclinical models of
the disease [4–7]. We also reported that optimization of curcumin
delivery, by using curcumin-loaded nanocapsules, has improved
its preclinical performance [8].
Despite the advances in the therapy of diverse cancers, glioblas-
toma patients still depend on the limited effectiveness of the
alkylating agent temozolomide (TMZ) in combination with neuro-
surgery and/or radiotherapy. Despite efforts for improvement,
including development of targeted therapies [9], prognosis remains
dismal, with a median survival of ~14 months. Most of the diﬃ-
culties in treating glioblastomas are a consequence of its localization
behind the blood–brain barrier (BBB), thus limiting the bioavailability
of chemotherapies. There are additional complications due to the
highly proliferative and inﬁltrative phenotype of the tumors that
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are driven by mutations in genes such as p53, EGFR and PTEN
[10].
Given the preclinical eﬃcacy of curcumin and the clinical rele-
vance of TMZ in treating glioblastomas, we tested whether curcumin
could increase the eﬃcacy of TMZ in vitro and in vivo. The experi-
ments were undertaken in order to investigate not only the synergy
between these drugs, but also the molecular mechanisms orches-
trating the effects of the curcumin/TMZ combination. Our data
pointed to a role for MAPKs and DNA-damage response (DDR) de-
pendent autophagy in protecting glioblastoma cells from apoptosis.
Blocking autophagy renders glioblastoma cells more sensitive to
curcumin and TMZ in both in vitro and in vivo models.
Materials and methods
Reagents
Curcumin, temozolomide, propidium iodide (PI), acridine orange, MTT (3-(4,5-
dimethyl)-2,5-diphenyl tetrazolium), BAY117082, 3-methyl-adenine (3-MA), UO126,
SP600129, SB203508, Stattic and LY294002 were from Sigma (São Paulo, Brazil). SDS/
PAGE and immunoblot reagents were from Bio-Rad (Hercules, CA, USA). The phospho-
p65Ser536 (#3033), phospho-STAT3Tyr705 (#9131), Bax (#2772), cyclin D1 (#2926),
phospho-Chk1Ser345 (#2348), phospho-cdc25cSer216 (#9528), caspase-3 (#9665), PARP
(#9532), BiP/GRP78 (#9956), CHOP (#2895), LC3A/B (#4108), phospho-mTORSer2448
(#2971), mTOR (#2972), ATG5 (#2630), ATG7 (#8558), p-ERK1/2Thr202/Tyr204 (#9101),
phospho-cdc2Tyr15 (#9111), phospho-ATMSer1981 (D25E5, #13050), phospho-
Histone H2AXSer139 (#2577), phospho-Wee1Ser642 (D47G5, #4910), cyclin B1 (V152,
#4135), phospho-p38Thr180/Tyr182 (3D7, #9215), phospho-SAPK/JNKThr183/Tyr185 (98F2,
#4671) and anti-rabbit/mouse IgG HRP-linked antibodies were from Cell Signaling
Technology (USA). The cyclin A (C-19), p-RbSer807/811 (sc-16670) and phospho-
PERKThr 981 (sc-32577) were from Santa Cruz Biotechnology.
Cell lines
C6, U251MG and U87MG cell lines were from American Type Culture Collec-
tion (ATCC) (Rockville, Maryland, USA). Primary astrocytes were isolated from
cortex of 2-days old Wistar rats by mechanical dissociation with Ca+2/Mg+2-free
Hank’s balanced salt solution, and plated in poly-L-lysine-coated plates as de-
scribed [11]. The cells were maintained in low-glucose DMEM plus antibiotics
(Gibco BRL, Carlsbad, USA) in a humidiﬁed incubator. TMZ, curcumin and inhibitor
stock solutions were dissolved in DMSO. The inhibitors were treated for 3 h prior
to TMZ/curcumin.
Viability assays
MTT reduction by cellular dehydrogenases was used as an estimation of cellu-
lar viability [11]. The leakage of lactate dehydrogenase (LDH) into culture medium
was measured following the CytoTox 96-NonRadioactive Cytotoxicity Assay kit in-
structions (Promega). For PI uptake, treated cells were incubated with 6 μM PI in
DMEM for 1 h, and images were obtained using a Nikon Eclipse TE 300 inverted mi-
croscope setup with rhodamine ﬁlter. Manual counting was performed by using a
hemocytometer.
Clonogenic survival assays
Exponentially growing cells (1 × 106) were plated in 6-well plates and then
treated for 72 h. After, the cells were trypsinized and 104 Trypan blue-negative
cells were re-plated in 6-well plates and maintained for an additional 9 days.
Viable colonies were stained with MTT (2 mg/mL) and manually counted under
magniﬁcation.
Cell cycle analysis
Treated cells were trypsinized, centrifuged and resuspended in 500 μL lysis buffer
(10 mM PBS, 0.1% v/v Nonidet P-40, 1.2 mg/mL spermine, 5 μg/mL RNAse, and
2.5 μg/mL propidium iodide/PI, pH 7.4). The cells were vortexed and incubated for
10min on ice. The DNA content was determined by FACS, and analyzed by CellQuest®
software (BD Biosciences, USA).
Western blots
Total cell lysates (~40 μg proteins) were separated by SDS-PAGE and
electrotransferred onto nitrocellulose membranes. The membranes were stained
with Ponceau, rinsed with TBS-T, blocked with 5% non-fat dry milk in TBS-T (1 h),
and then incubated with primary antibodies (1:1000; 4 °C, overnight). Afterwards,
the membranes were incubated with HRP-linked anti-IgG (1:3000, 2 h/room tem-
perature), and the chemiluminescent bands were detected using X-ray ﬁlms.
Annexin-V/PI staining
The Annexin V-FITC Apoptosis Detection Kit (Sigma-Aldrich) was used for quan-
tiﬁcation of apoptosis. After trypsinization, externalized phosphatidylserine was
labeled with annexin-V-FITC-conjugated for 15 min on ice. Propidium iodide
(PI, 1 μg/mL) was added 10 min prior to FACS analysis. Viable (annexin−/PI−), early
(annexin+/PI−) and late apoptotic (annexin+/PI+), and necrotic cells (annexin−/PI+)
were assigned. Data were analyzed by CellQuest® software (BD Biosciences, USA).
Caspase-3/7 activity
The caspase-3/7 activity was assessed following CASP3F Fluorimetric kit in-
structions (Sigma, Saint Louis/MI). After whole-cell extracts preparation, 150 μg
proteins (Bradford method) were mixed with 200 μL of assay buffer containing Ac-
DEVD-AMC, a caspase-3-speciﬁc substrate. Ac-DEVD-AMC cleavage was monitored
for 1 h at 37 °C in a ﬂuorescence reader (Ex/Em: 360/460 nm).
Comet assay
Brieﬂy, 2 × 104 cells in 20 μL DMEMweremixedwith 80 μL of low-melting agarose
(0.75%), and added to a 1.5% agarose-coated microscope slide. The slides were placed
into a lysis solution (2.5 M NaCl, 100 mM EDTA and 10 mM Tris, pH 10.5, plus 1%
Triton X-100 and 10% DMSO) overnight at 4 °C, electrophoresed in alkaline solu-
tion (300 mM NaOH and 1 mM EDTA) during 20 min at 25 V (0.90 V/cm; 300 mA),
neutralized with 400 mM Tris (pH 7.5), washed with dH2O, and stained with SYBR
Safe. Hundred cells per sample were counted and classiﬁed based on the tail length
using a ﬂuorescence microscope. Comet Index (CI) was calculated as follows:
CI = [(n°type1) × 1 + (n°type2) × 2 + (n°type3) × 3 + (n°type4) × 4], where “n° type X”
is the number of cells carrying a type X of DNA damage.
Acridine orange staining
Acridine orange (AO) is a probe that ﬂuoresces green in the whole cell except in
acidic compartments,where it ﬂuoresces red.Vacuolar acidiﬁcationof autophagosomes
is a characteristic of eﬃcient autophagy, thus the red ﬂuorescence is proportional to
autophagy. Treated cells were incubated with AO (1 μg/mL) for 15 min, trypsinized,
centrifuged, and resuspended in PBS. The green/red (FL1-H/FL3-H) ﬂuorescencewas
detected using a FACSCalibur, and acridine orange positive cells (AO+) were quan-
tiﬁed by CellQuest® software (BD Biosciences, San Jose, USA).
Small interference RNA (siRNA)
For siRNA procedures, the cells were transfected using the Lipofectamine RNAiMax
(Invitrogen, USA) by reverse transfection (20–30 nM siRNA). Protein knockdown was
conﬁrmed by western blot. Human ATG7 (Autophagy-related 7 homolog) siRNA was
from Cell Signaling (#6604); ATM (Ataxia telangiectasia mutated) siRNA (sc-29761)
was from Santa Cruz; and MSH6 siRNA (#144497) was from Invitrogen. Silencer®
Select Control#1 siRNA was used as a scrambled control.
STAT3 and NFκB DNA-binding activity
TransAM™ STAT3 and TransAM® Flexi NFκB p65 ELISA kits were used to address
the DNA-binding activity of these transcription factors according to manufacturer
instructions (Active Motif Inc., USA). Nuclear extracts were prepared as previously
described [11]; 10 μg of soluble nuclear protein fractions was assayed.
Immunoﬂuorescence
Coverslip seeded cells were treated and ﬁxed in 4% paraformaldehyde/PBS, rinsed
and permeabilized with ice-cold 100% methanol (10 min, −20 °C). The cells were
blocked with 5% horse serum/PBS (1 h), and then incubated with rabbit anti-
LC3A/B antibody (1:500; overnight/4 °C) followed by anti-rabbit IgG Alexa 594-
conjugated (1:500/2 h at room temperature). For nuclear staining, Prolong Gold
Antifade Reagent with DAPI (Molecular Probes, P36931) was used. Images were taken
with an Olympus FluoView™ 1000 confocal microscope and analyzed by ImageJ®.
Immunohistochemistry (IHC)
Cryostat sections from C6 tumors or human glioblastoma specimens were
deparaﬃnized, unmasked using citrate method, and blocked in 1% albumin. Anti
p-ERK1/2 (E4, sc-7383, 1:100; Santa Cruz) or anti-LC3A/B (1:200) primary antibod-
ies were incubated overnight at 4 °C. The sections were then incubated with
biotinylated secondary antibody followed by streptavidin–avidin–biotin (kit Lsab,
Dako, CA, USA). The peroxidase reaction was performed using DAB counterstained
with Harris hematoxylin. Human glioblastoma specimens were obtained from Hos-
pital Sao Vicente de Paulo, Universidade de Passo Fundo (UPF), and approved by UPF
Ethical Committee (Approval N° 200/2011).
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Animal studies: C6 glioma model
C6 cell brain implants were performed as previously described [3,8]. C6 cells
(0.8 × 106/3 μL) were injected with a Hamilton microsyringe coupled with an infu-
sion pump into the right striatum of 8-weeks-old male Wistar rats pre-
viously anesthetized by ketamine/xylazine. Animal studies followed the “Policy on
Humane Care and Use of Laboratory Animals” of the NIH and institutional policy,
and were approved by local Ethics Committee for Animal Experimentation (Proto-
col: 23810). After 7 days for tumor establishment, the animalswere grouped as follows
(n = 9–11/group): Vehicle (DMSO); Curc (Curcumin 50 mg/kg); RSV (Resveratrol
10 mg/kg); TMZ (temozolomide 10 mg/kg); TMZ + Curc (TMZ 10 mg/kg + Curcumin
50 mg/kg); TMZ + RSV (TMZ 10 mg/kg + RSV 10 mg/kg); TMZ + Curc + RSV (TMZ
10mg/kg +Curcumin50mg/kg +RSV10mg/kg);TMZ +CQ(TMZ10mg/kg +Chloroquine
20 mg/kg); TMZ + Curc + CQ (TMZ 10 mg/kg + Curcumin 50 mg/kg + Chloroquine
20 mg/kg); CQ (Chloroquine 20 mg/kg). TMZ was administrated thrice a week;
curcumin, RSV and CQ were administrated daily (i.p.). In combinations, the solu-
tionsweremixed, and a single injectionwas applied. The rats were decapitated after
14 days of treatment. The brainwas removed, ﬁxedwith 10% paraformaldehyde and
paraﬃnembedded. ThreeH&E-stained coronal sections (3 μm thick) fromeach animal
were analyzed. Images were captured, and the tumor area (mm3) was determined
as described [3,8].
Statistical analysis
The in vitro experiments were repeated at least three times in triplicates. For
the in vivo model, the number of animals was based on previous calculations [3,8].
Data were expressed as average ± SD. ANOVA followed by Tukey and Newman–
Keuls post-hoc were used (Prism Graphpad®). p < 0.05 was assumed as signiﬁcant.
Results
Combination of TMZ and curcumin exerts additive cytotoxicity to
glioblastoma cells
We ﬁrst determined the effect of TMZ on viability of glioblas-
toma cell lines harboring different mutations. C6 (p53wt/PTENmut/
p16del) were more sensitive to TMZ than U251MG (p53mut/PTENnull/
p16del) and U87MG (p53wt/PTENmut/p16del) (Fig. 1A, top graph). Given
that we previously validated curcumin eﬃcacy in vitro and in vivo
[3], we were expecting curcumin to sensitize glioblastomas to
TMZ. However, the viability assays showed that the effects of TMZ/
curcumin combination were additive instead of synergistic (Fig. 1A).
Note that co-treatments were harmless to astrocytes, indicating
selective toxicity to transformed glia (Fig. 1A).
Up to 48 h, TMZ and curcumin decreased the cell numbers, but
no signiﬁcant PI incorporation was observed (Fig. 1B and C). Time-
course experiments showed that the decreases in cell proliferation
(by cell counting assays) preceded PI incorporation, suggesting
that growth inhibition is an early step of TMZ/curcumin cytotox-
icity (Fig. 1B). On the other hand, pronounced changes in cell
morphology and PI incorporation were observed at high curcumin
(≥30 μM for glioblastomas; ≥60 μM for astrocytes) (Fig. 1C) thus
making co-treatment of these concentrations with TMZ unfea-
sible. In addition, clonogenic survival assays indicated that 72 h
incubation with TMZ/curcumin led to prolonged growth inhibi-
tion of surviving clones compared to single agents at the same
concentration (Fig. 1D).
The therapeutic beneﬁt of TMZ depends on its ability to meth-
ylate DNA at N-7 or O-6 positions of guanine, which leads to DNA
strand breaks and activation of DDR pathways. Comet assays showed
that curcumin/TMZ combination induced substantial levels of DNA
damage compared to single agent treatments (Fig. 1E). In addi-
tion, both curcumin and TMZ promoted phosphorylation of the
DNA double-strand break sensors H2AX and ATMSer1981, but no
further increase was obtained in co-treatments (Fig. 1F). Based on
the non-synergistic patterns of viability changes observed in this
ﬁrst set of experiments, we hypothesized that curcumin and TMZ
may inhibit cell growth via the same mechanism. Hereafter we
sought to determine the mechanisms whereby cells resist the
TMZ/curcumin combinations.
G2/M checkpoint activation precedes apoptosis in TMZ/curcumin
treated cells
TMZ is known to cause G2/M arrest in glioblastomas [12]. There-
fore, we asked whether TMZ-induced changes in cell cycle arrest
could be altered by curcumin. At the end of 72 h treatment, both
curcumin and TMZ redundantly induced accumulation of cells in
G2/M, an effect evenmore pronounced in drug combinations (Fig. 2A,
top panels). Western blot analysis showed that multiple G2/M
checkpoint proteins were activated by curcumin and TMZ individ-
ually, such as phosphorylation of WeeSer642, Cdc2Tyr15, CHK1Ser345
and Cdc25cSer216. Co-treatment of curcumin and TMZ caused minor
further induction, with the exception phospho-CHK1 levels (Fig. 2B).
Corroborating the G2/M checkpoint activation, we observed that
phosphorylation of cyclin B1 and cyclin D1 decreased following
treatment by either drug (Fig. 2B). By extending drug incuba-
tions for longer periods (96 h in C6 and 120 h in U251MG), we
were able to detect sub-G1 apoptotic phenotypes as assessed by
cell cycle analysis, implying that G2/M checkpoint activation and
cell proliferation inhibition preceded cell death (Fig. 2A, bottom
panels).
By using Annexin-V/PI assays, we observed that glioblastoma
cells were differentially sensitive to TMZ/curcumin induction of
apoptosis. While C6 cell apoptosis was detected from 48 h, U251MG
(Fig. 2C) and U87MG (data not shown) only succumbed to low
levels of apoptosis after 96 h treatment. The pan-caspase inhibi-
tor Z-VAD-fmk inhibited this phenomenon, indicating a caspase-
mediated mechanism (Fig. 2C). In fact, caspase-3/7 activity was
increased in total extracts of TMZ and curcumin-treated C6 and
U251MG cells; higher levels of activity were observed in co-
treatments likely due to additive effects (Fig. 2E). As a control, the
proteasome inhibitor MG132 (5 μM) caused a pronounced activa-
tion of caspase-3/7 [13], implying that the limited effect of curcumin
and TMZ was not related to an intrinsic dysfunction of apoptosis
in glioblastoma cells, but more likely the activation of protective
mechanisms.
Autophagy as an early event in TMZ and curcumin-treated
glioblastomas
Taking into account the results thus far, we decided to test
whether cell resistance could be attributed, at least in part, to
autophagy. By ﬂow cytometry, we observed that both cur-
cumin and TMZ promoted autophagy, which was stimulated further
by curcumin/TMZ co-treatment (Fig. 3A and B). Autophagy oc-
curred earlier than apoptosis, being evident from 24 h treatment
across the cell lines (Fig. 3A). To conﬁrm these observations we
observed the presence of autophagosome punctae containing LC3
proteins by immunoﬂuorescence following TMZ and curcumin alone,
and particularly co-treatment (Fig. 3C). To corroborate the induc-
tion of autophagy we also noted changes in the immunocontent
of several proteins involved in autophagy [14–16]; mTOR phos-
phorylation (Ser2448), induction of ATG5 and ATG7, and conversion
of LC3-I to LC3-II (lipidated form) (Fig. 3D). Further, we examined
markers of endoplasmic reticulum (ER) stress, a known inducer of
autophagy by TMZ in glioblastomas [14,15], and observed that the
ER chaperone GRP78/BIP, CHOP and p-PERK were up-regulated by
curcumin/TMZ (Fig. 3D). Note that TMZ/curcumin combination did
not seem to affect many of these markers when compared to
monotreatments, except for p-mTOR levels, which signiﬁ-
cantly dropped in drug combinations (Fig. 3D). Finally, in a more
limited analysis, we observed that LC3-containing vacuoles were
also detectable in tumor tissues from glioblastoma patients treated
with TMZ as assessed by IHC (Fig. 3E). Ki67 staining was used as a
positive marker of proliferative cells within the tumor specimen.
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Fig. 1. Curcumin and TMZ induce additive cytotoxicity in glioblastomas. (A) MTT viability experiments showing the effect of TMZ alone (top graph), and curcumin and TMZ/
curcumin combinations in U251MG, U87MG and C6 cells, as well as primary astrocytes. (B) Representative graphs showing the cell counts versus PI uptake in C6 and U251MG
treated with TMZ plus/or 15 μM curcumin. (C) Representative phase contrast and PI uptake microphotographs in TMZ/curcumin-treated cells for 48 h (10× magniﬁcation,
bar: 100 μm). If not speciﬁed, C6 cells were treated with 200 μM TMZ; 400 μM TMZ was used in U87MG, U251MG and astrocytes. (D) Long-term survival and representa-
tive colony staining in C6 cells. (E) Comet assays in TMZ/curcumin treated U251MG cells and quantiﬁcation of DNA damage index. (F) Representative immunoblots showing
H2AX and ATM phosphorylation in U251MG cells. If not speciﬁed, 72 h treatments were performed. * Different from control (vehicle-treated) or for indicated comparisons;
#different from curcumin and TMZ alone at equivalent drug concentrations (n = 3 in triplicate, p < 0.05, ANOVA).
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Fig. 2. Curcumin and TMZ effects on cell cycle arrest and apoptosis in glioblastomas. (A) Cell cycle analysis of C6 and U251MG cells treated with curcumin and TMZ for
different times. (B) Representative immunoblots of cell cycle regulatory proteins after 72 h curcumin and TMZ incubation. (C) Annexin-V/PI ﬂow cytometry assays showing
the time-course of TMZ- and curcumin-induced apoptosis in glioblastoma cells, and (D) representative Annexin-V/PI dot-plots showing the additive effect of TMZ and curcumin
(+/− Z-VAD-fmk, 50 μM) on apoptosis of glioblastoma cell lines. Upper-right (UR) and lower-right (LR) quadrants quantiﬁcation is also shown. (E) Caspases-3/7 activity in
TMZ/curcumin treated cells as expressed as % of controls. If not speciﬁed, C6 and U251MG cells were treated with 200 and 400 μM TMZ, respectively, in the presence of
15 μM curcumin. * Different from control; #different from curcumin and TMZ alone, considering equivalent drug concentrations (n = 3 in triplicate, p < 0.05, ANOVA).
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Fig. 3. Autophagy as a major response of glioblastoma cells to TMZ and curcumin. (A) Time-course quantiﬁcation of autophagy and (B) representative dot-plot graphs of
acridine orange (AO) ﬂow cytometry assay in TMZ/curcumin treated C6 and U251MG cells. AO+: acridine orange positive cells (red ﬂuorescence) are quantiﬁed. (C) Immu-
noﬂuorescence detection of LC3-positive vacuoles in U251MG cells (Bar: 20 μm). (D) Representative immunoblots showing the effect of TMZ and curcumin on the immunocontent
of autophagy and ER stress protein markers in U251MG. When not speciﬁed, C6 and U251MG/U87MG cells were treated for 72 h with 200 and 400 μM TMZ, respectively,
in the presence of 15 μM curcumin. (E) IHC analysis of LC3 and Ki67 in tumor specimens from glioblastoma patients treated with TMZ (Bar: 20 μm). * Different from control;
#different from curcumin and TMZ alone considering equivalent drug concentrations (n = 3 in triplicate, p < 0.05, ANOVA). (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Autophagy inhibition abrogates G2/M arrest and favors apoptosis
ATG family proteins and class III PI3K kinases such as Vps34 are
critical regulators of autophagy. ATG7 is an E1-like activating enzyme
that activates ATG12 for its conjugation with ATG5, as well as LC3
conjugation with phosphatidylethanolamine; these are two criti-
cal events during autophagosome formation. Fig. 4A shows that TMZ/
curcumin-induced autophagy was blocked by ATG7 knockdown and
class III PI3K inhibitor 3-MA (see knockdown validation in Fig. S1).
Inhibition of autophagy potentiated the cytotoxicity of curcumin or
TMZ as well as TMZ/curcumin combination as determined by MTT
(Fig. 4B) and LDH leakage (Fig. 4C) assays.
The observed potentiation of TMZ/curcumin cytotoxicity by au-
tophagy inhibition seems to be attributable to a switch from
autophagy to apoptosis. This conclusion is supported by the in-
creased percentage of Annexin-V positive cells (Fig. 4D) and caspase-
3/7 activity (Fig. 4E) when ATG7 was knocked down or 3-MA pre-
treatments were performed. Similar patterns were observed when
cells were treated with the late autophagy inhibitor chloroquine (CQ,
15 μM) (Fig. 4B–E). Autophagy inhibition increased BAX, cleaved-
caspase-3 and cleaved-PARP1 immunocontents in U251MG cells
(Fig. 4G). Interestingly, blocking autophagy also resulted in de-
creased induction of p-WeeSer642, p-Ccd2tyr15 and p-Cdc25C by
curcumin/TMZ (Fig. 4G). Concomitantly, we observed an attenu-
ated G2/M arrest as determined by cell cycle analysis (Fig. 4F). While
C6 cells arrested in G1/S, U251MG arrested in the S-phase in the
presence of 3-MA (Fig. 4F); the levels of p-RbSer807/811 increased under
these experimental conditions (Fig. 4G). Of note, when cells were
treated with curcumin/TMZ for 24 h and then post-treated with
3-MA, the attenuation of the G2/M arrest was not observed (data
not shown), indicating that early autophagy is coordinatedwith G2/M
checkpoint activation. In vivo, CQ, which was shown to block on-
colytic adenovirus dl922-947 [17] and PI3K/mTOR dual inhibitor
NVP-BEZ235-induced autophagy in glioblastomas in vivo [18], im-
proved the eﬃcacy of TMZ and TMZ/curcumin in rat brain-implanted
C6 cells (Fig. 4H). Total inhibition of tumors was not achieved in CQ
co-treatments, probably due to in vivo factors such as tumor acidic
pH-mediated CQ inactivation [19] and/or restrictions imposed by
the BBB.
Curcumin and TMZ both require ERK1/2 to induce autophagy
Given that autophagy conferred resistance, we screened the con-
tribution of several pathways that are known to be important for
glioblastoma survival for their potential role in regulating the
autophagy/apoptosis balance in response to TMZ and curcumin. Ini-
tially, we used speciﬁc pharmacological inhibitors of STAT3 (Stattic),
IKK/NFκB (BAY117082), PI3K (LY294002) and ERK1/2, p38 and
JNK1/2 MAPKs (UO126, SB203508 and SP600129, respectively)
(Figs. 5A and S1). From this analysis we observed that blocking basal
NFκB and STAT3 induced substantial levels of autophagy, mild apop-
tosis and high cytotoxicity. Other inhibitors had no signiﬁcant effect
on apoptosis/autophagy but decreased cell proliferation (Figs. 5A and
S1). We then tested whether curcumin or TMZ could modulate the
activity of these pathways. TMZ stimulated the three MAPKs in
U251MG cells (Fig. 5B). Curcumin altered neither basal nor TMZ-
induced p38/JNK1/2 phosphorylation, but caused strong ERK1/2
activation alone or in combination with TMZ. In addition, curcumin
blocked both basal and TMZ-induced p-p65 (Fig. 5B) and NFκB DNA-
binding, as indicated by immunoblot and ELISA assays, respectively
(Fig. 5C). In addition, curcumin also decreased STAT3 phosphory-
lation and its DNA-binding (Fig. 5B and C), while also inhibiting the
phosphorylation of the PI3K target, AKT (Fig. 5B); TMZ had no effect
on these proteins.
MAPKs modulate both TMZ chemoresistance and G2/M arrest
[20–22], but little is known regarding TMZ-induced autophagy.
Considering the presence of DNA damage in response to TMZ and
curcumin treatment that we observed, we also tested the contri-
bution of the DDR pathway via ATM and themismatch repair protein
MSH6. Both of these proteins were recently described as media-
tors of DNA damage induced autophagy in LN229 and U87MG cells
[20]. Knockdown of ATM or MSH6 (with siRNA), as well as inhibi-
tion of p38 or JNK1/2, switched cells from autophagy to apoptosis
in TMZ and TMZ/curcumin, but not curcumin alone, indicating a
dominant role of DDR and JNK/p38 in TMZ-induced autophagy
(Fig. 5D). Combinations with STAT3 and NFκB inhibitors were un-
feasible due to excessive toxicity of these inhibitors by themselves
(Fig. S1), agreeing with previous studies [9,11].
Among the pathways targeted in our limited screening, ERK1/2
stood out as a potentially overlapping mechanism; both TMZ and
curcumin, as well as co-treatments, stimulated ERK1/2 phosphory-
lation (Fig. 5B). Further, inhibition of ERK1/2 suppressed autophagy
(Fig. 5D and E) and enhanced apoptosis (Fig. 5D). Similar patterns
were observed with the PI3K inhibitor LY294002 (Fig. 5D and E). Cor-
roborating these observations, TMZ/curcumin combinedwith ERK1/2
and PI3K inhibitors enhanced caspase-3 cleavage and activity, and
BAX immunocontent (Fig. 5F). ERK1/2 and PI3K seem to partici-
pate in the early steps of autophagy as UO126 and LY294002
inhibited LC3-I conversion to LC3-II (Fig. 5F). In keeping with our
3-MA data (Fig. 4), UO126 and LY294002 co-treatments caused in-
hibition of G2/M checkpoint as determined by cell cycle analysis
(Fig. 5H) and immunoblots against p-Wee, p-Cdc2 and p-Cdc25C pro-
teins (Fig. 5F). When the cells were treated for 3 days with TMZ/
curcumin plus inhibitors were monitored for an additional 3 days
to allow for recovery, we observe that the inhibitors that also blocked
autophagy made the cells more susceptible to TMZ/curcumin
(Fig. 5G). A residual number of cells were detectable in every treat-
ment at 6 days, indicating that resistant clones or long-term
processes, such as senescence, were also taking place (Fig. S2).
Inhibition of ERK1/2-dependent autophagy by resveratrol improves
TMZ and curcumin eﬃcacy in vivo
Based on our observations thus far, we decided to test our ﬁnd-
ings to determine whether autophagy limits the eﬃcacy of TMZ/
curcumin treatment in glioblastomas. Key to this strategy is the
requirement for a small-molecule inhibitor with the ability to cross
BBB and modulate autophagy in glioblastomas. A recent study
showed that resveratrol (RSV) is able to block TMZ-induced au-
tophagy and enhance apoptosis through inhibition of ERK1/2 in
U87MG and GBM8401 cells in vitro [23]. In contrast, others have
reported that RSV induced autophagy in U87MG and U138MG [24],
but potentiated TMZ effects by blocking the G2/M checkpoint [25].
In our studies we found that with U251MG cells, RSV synergized
with TMZ and curcumin in short- (Fig. 6A) and long-term viability
assays (Fig. 6B). Although the aforementioned studies [23,24] re-
ported opposing results, our data revealed that RSV has dual effects
that are concentration-dependent (Fig. 6C). We found that low levels
of RSV (up to 15 μM) blocked TMZ, curcumin and TMZ/curcumin-
induced autophagy (Fig. 6D and E) and LC3 conversion (Fig. 6F), thus
promoting apoptosis (Fig. 6E). RSV also inhibited G2/M check-
point and ERK1/2 phosphorylation (Fig. 6D and F), which emulated
the 3-MA and UO126 effects we previously observed. In contrast,
higher levels of RSV alone (30–60 μM) induced autophagic and
apoptotic cell subpopulations (Fig. 6C).
To test the utility of this strategy in vivo, our collaborators per-
formed complete pharmacokinetics analysis to show that RSV (i.p.
and oral) reaches the brain of Wistar rats at levels (1–5 μg/g tissue)
enough to attenuate Alzheimer-related dysfunctions [26,27]. These
results support the potential of this chemical to be used in associ-
ation with TMZ/curcumin in C6 cell brain implants. In our model,
curcumin and TMZmono-treatments decreased C6 cell brain tumors,
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Fig. 4. Autophagy inhibition sensitizes TMZ and curcumin treated cells to apoptosis. (A) Dot-plot ﬂow cytometry graphs showing the 3-MA and ATG7 siRNA effect on au-
tophagy in U251MG cells (AO staining). (B) MTT, (C) LDH leakage, (D) Annexin-V/PI ﬂow cytometry and (E) caspase-3/7 activity assays showing the impact of autophagy
inhibitors on viability and apoptosis of U251MG cells. (F) Representative cell cycle distribution graphs and quantiﬁcation in C6 and U251MG cells. (G) Representative immunoblots
of cell cycle and apoptotic markers in U251MG cells treated in the presence or absence of 3-MA. If not speciﬁed, C6 and U251MG cells were treated for 72 h with 200 and
400 μM TMZ, respectively, in the presence of 15 μM curcumin. AO+: acridine orange positive cells (red ﬂuorescence). (H) Effect of CQ treatment on C6 tumor growth in TMZ
and TMZ/curcumin-treated rats. Details are provided in Materials and Methods section. Legends: 3-MA (4 mM), CQ (15 μM chloroquine, in vitro); ATG7si (ATG7 siRNA). Data
are expressed as average ± SD. * Asterisks denote signiﬁcation for indicated comparisons (n = 3, p < 0.05, ANOVA). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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Fig. 5. ERK1/2 activation as a redundant mechanism of curcumin and TMZ-induced autophagy. (A) Effect of MAPKs, PI3K, JAK/STAT3 and IKK/NFκB inhibitors on viability
(MTT), autophagy (AO ﬂow cytometry analysis) and apoptosis (Annexin-V/PI ﬂow cytometry) in U251MG cells after 72 h treatment. (B) Representative immunoblots showing
the effect of TMZ, curcumin and TMZ/curcumin combination on MAPKs (ERK1/2, p38 and JNK1/2), Akt, p65-NFκB and STAT3 phosphorylation in U251MG cells. (C) ELISA
assays showing NFκB and STAT3 DNA-binding activity in nuclear extracts of TMZ and/or curcumin-treated U251MG (24 h treatment). (D) Effect of various inhibitors on
autophagy and apoptosis of U251MG cells after 72 h and (E) representative graphs of AO ﬂow cytometry in the presence of UO126 and LY294002. AO+: acridine orange
positive cells (red ﬂuorescence). (F) Representative immunoblots showing the effect of UO126 and LY294002 on cell cycle and apoptotic proteins, and caspase-3/7 activity
in TMZ/curcumin-treated U251MG cells (72 h). (G) Long-term survival of TMZ/curcumin-treated U251MG cells in the presence of various pathway inhibitors (MTT assay).
(H) Cell cycle analysis showing the effect of UO126 and LY294002 on TMZ/curcumin-induced G2/M arrest. Legend: UO126 (UO), SP600129, SB208503 and LY294002 (LY)
were incubated at 20 μM, BAY117082 and Stattic were used at 5 and 1 μM, respectively. * Different from control cells and for indicated comparisons; #different from TMZ/
curcumin combination (n = 3 in triplicate, p < 0.05, ANOVA).
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Fig. 6. Resveratrol improves TMZ/curcumin eﬃcacy via inhibition of ERK1/2-dependent autophagy. (A) MTT and (B) long-term clonogenic assays showing the sensitizing
effect of RSV in U251MG cells. (C) Dose–effect of RSV on autophagy and apoptosis in U251MG cells as assessed by AO and Annexin-V/PI ﬂow cytometry assays, respectively.
(D) Representative dot-plots of AO ﬂow cytometry, (E) quantiﬁcation of TMZ/curcumin induced autophagy and apoptosis, and (F) cell cycle distribution in U251MG cells
treated with or without 15 μM RSV. AO+: denotes acridine orange positive cells (red ﬂuorescence). (G) Immunoblots showing the RSV effect on phosphorylation of cdc2,
Wee, ERK1/2 and Akt, caspase-3 cleavage, and LC3 content in U251MG. Otherwise speciﬁed, cells were treated with 400 μM TMZ and 15 μM curcumin, and 72 h treatments
were carried out. (H) Brain-implanted C6 tumors size and (I) IHC analysis of C6 tumors showing the levels of p-ERK1/2, LC3 and ATG7 in the presence or absence of RSV
(bar: 20 μm). Western blots for ERK1/2 forms, ATG7 and LC3 immunocontents in tumor lysates are also shown. *Different from control; asterisks also denote signiﬁcation
for indicated comparisons; #different from control, TMZ and TMZ/curcumin at equivalent doses; a Denotes the effect of RSV in inhibiting TMZ/curcumin-induced au-
tophagy. (n = 3 in triplicate, p < 0.05, ANOVA). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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but TMZ/curcumin combinations did not elicit additional reduc-
tion in tumor sizes. Co-regimen of TMZ/curcumin plus RSV induced
signiﬁcantly smaller tumors compared to TMZ/curcumin and TMZ/
RSV (Fig. 6G). IHC and Western blot analysis showed that TMZ/
curcumin combination increased p-ERK1/2, LC3 and ATG7 in tumor
tissues from C6 cells implants (Fig. 6H), suggestive of autophagy in
vivo. These alterations were reversed by RSV co-treatment (Fig. 6H),
indicating that RSV in vitro ﬁndings upon ERK1/2 and autophagy
are tangible in vivo.
Discussion
Even though TMZ is the chemotherapeutic that has demon-
strated the best clinical performance in glioblastomas, combined
therapies aiming to improve its eﬃcacy are still a pressing goal in
the ﬁeld. Given the eﬃcacy of curcumin in a variety of in vitro and
preclinical models [3–7], we developed a series of experiments in
order to evaluate the potential of combining curcumin with TMZ
in models of glioblastoma. In vitro, TMZ/curcumin co-treatments
were more cytotoxic than its respective mono-treatments, al-
though the effects were additive rather than synergistic. In vivo,
combining curcumin with TMZ did not translate to any signiﬁcant
reduction of tumor volume compared to TMZ alone. The investi-
gations outlined here demonstrate that autophagy is a mechanism
involved in the observed resistance.
The relationship between autophagy and apoptosis is complex
in the sense that, depending on the scenario, autophagy consti-
tutes a stress adaptation that can suppress apoptosis. However, in
other contexts, autophagy constitutes an alternative pathway to cel-
lular demise (reviewed in ref. 28). When autophagy is blocked either
at earlier or later stages, it may lead to apoptosis as a result of the
failure to adapt to cell stresses. For example, Bax−/− Bak−/− mouse cells
are normally resistant to cell stress induced apoptosis except when
autophagy is inhibited by ATG5 or ATG7 depletion or 3MA treat-
ment. On the other hand, cells with dysfunctional apoptosis also
may undergo autophagic cell death [28]. Thus, the timing and mag-
nitude of the cellular stresses, in keepingwith cellular characteristics,
seem to dictate the decision between autophagy and apoptosis, and
whether autophagy is involved in cell death or survival.
Autophagy has, in fact, been reported as a mechanism of glio-
blastoma survival to xenobiotics, including TMZ [18,20,23]. In our
model, autophagy occurred concomitantly with G2/M arrest, and
these events preceded apoptosis. TMZ/curcumin treatments in com-
bination with 3-MA, chloroquine or ATG7 siRNA resulted in cell
viability decreases, LDH leakage as well as expression of apoptotic
markers, suggesting a protective autophagy. Supporting our ﬁnd-
ings in U251MG and C6, 3-MA potentiated TMZ toxicity by rendering
LN229 and U87MG cells to apoptosis [20].
Diverse pathways were differentially modulated by curcumin and
TMZ to promote autophagy. TMZ, as an alkylating agent, activated
DDR-dependent autophagy, which involved DNA strand break sensor
and mismatch repair proteins ATM and MSH6, agreeing with ref.
20. Curcumin induction of autophagy seems to involve the inacti-
vation of NFκB and STAT3 signaling. Noteworthy, STAT3 inhibition
may also be attributing to part of the antiglioblastoma activity of
curcumin in vivo [7]. In fact, these pathways are constitutively up-
regulated in glioblastomas [2,3,6,29], and our experiments with
speciﬁc inhibitors pinpointed that interfering with these path-
ways is suﬃcient to trigger autophagy and apoptosis, thereby
recapitulating curcumin effects.
Not exclusive to DDR, TMZ pro-autophagy also involved the three
MAPKs. JNK1/2 and p38 are known to promote G2/M checkpoint
and survival of TMZ [21,22,30]. Here, we showed that JNK/p38 also
controls TMZ, but not curcumin, induced autophagy. On the other
hand, ERK1/2 was identiﬁed as an overlapping component of both
TMZ and curcumin-induced autophagy through regulation of the
early steps of autophagosome formation [31], for example by LC3
lipidation. Corroborating previous studies, high curcumin doses
(40 μM) stimulated ERK1/2-dependent autophagy in vitro, and de-
creased tumors in ﬂank-implanted U87MG [6]. In addition, TMZ alone
was recently described to cause ERK1/2-dependent autophagy in
U87MG in vitro and in vivo [23]. In our model, not exclusive of in
vitro settings, TMZ/curcumin co-treatments increased ERK1/2 phos-
phorylation as well as LC3 conversion and ATG7 in brain-implanted
C6 tumors. This model has the advantage of parsing out anti-
tumor immune responses while retaining an enriched tumor
microenvironment [32]. Overall, it supports that ERK1/2-dependent
autophagy is not exclusive to in vitro conditions. CQ and RSV ex-
periments showed that autophagy could be targeted as a means to
achieve better therapeutic eﬃcacy in vivo. Also, the potentiation of
both TMZ and TMZ/curcumin eﬃcacy through inhibition of ERK1/
2-mediated autophagy reveals a novel mechanism of RSV action in
vivo. RSV is well-tolerated and supported by extensive literature,
including clinical trials [33].
Blocking autophagy inhibits TMZ/curcumin G2/M arrest in our
model. Although this regulation awaits further study, there is some
evidence that autophagy inhibition blocks G2/M arrest caused by
artesunate in MCF7 and MDA-MB231 breast cancers [34]. Addi-
tionally, ATG7 silencing, 3-MA or baﬁlomycin A1 disrupted AO-
1012-induced S-phase arrest, leading to apoptotic cleavage of
caspase-9 and PARP1 [35]. Despite the yet described preclinical ef-
ﬁcacy of curcumin and the clinical usefulness of TMZ to treat human
glioblastoma, our data predict that TMZ and curcumin synergism
is unlikely to be achieved due to redundant mechanisms leading
to protective autophagy. Autophagy may be modulated to re-
sensitize glioblastoma cells to TMZ and curcumin in vitro and, more
importantly, in vivo. In conclusion, our ﬁndings support that small-
molecule autophagy inhibitors able to cross BBB could optimize TMZ
therapy.
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